B cell activating factor (BAFF) and BAFF receptors: fakes and facts

Gianfranco Ferraccioli, Elisa Gremese

Risultato della ricerca: Contributo in rivistaArticolo in rivista

12 Citazioni (Scopus)


Analysis of B cell activating factor (BAFF) receptors before and after B cell depletion therapy (BCDT) might offer a clue to the understanding of whether some B cell subsets may represent useful biomarkers of biological and clinical responses. Among the BAFF receptors in a cohort of rheumatoid arthritis (RA) patients, the AA have shown, by fluorescence activated cell sorter (FACS) analysis of median fluorescence intensity (MFI), that transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) and B cell maturation antigen (BCMA) do not change, whereas the most important, BAFF receptor 3 (BR3), appears to be decreased before as well as after BCDT in all B cell subsets but not in plasmablasts, the most important subset, depleted by BCDT.
Lingua originaleEnglish
pagine (da-a)291-292
Numero di pagine2
RivistaClinical and Experimental Immunology
Stato di pubblicazionePubblicato - 2017


  • Animals
  • Arthritis, Rheumatoid
  • B cell depletion therapy
  • B-Cell Activating Factor
  • B-Cell Activation Factor Receptor
  • B-Lymphocytes
  • BAFF
  • BAFF receptors
  • BR3
  • Flow Cytometry
  • Humans
  • Immunology
  • Immunology and Allergy
  • Lymphocyte Depletion
  • Transmembrane Activator and CAML Interactor Protein
  • rheumatoid arthritis


Entra nei temi di ricerca di 'B cell activating factor (BAFF) and BAFF receptors: fakes and facts'. Insieme formano una fingerprint unica.

Cita questo